small molecule

ELIQUIS

APIXABAN

Loss of exclusivityAugust 2031latest FDA-listed patent expiry

CompanyBRISTOL MYERS SQUIBB CO PHARMACEUTICAL RESEARCH INSTITUTE

Drug detail

Brand name	ELIQUIS
Active ingredient	APIXABAN
Strength	0.5MG
Dosage form	TABLET, FOR SUSPENSION
Route	ORAL
Modality	Small molecule
FDA approval	April 2025
Marketing status	RX

Listed patents

Patent	Expires	Type
9326945*PED	August 2031	—
9326945	February 2031	product
6967208*PED	May 2027	—
6967208	November 2026	substance, product

Regulatory exclusivity

Code	Expires
PED	October 2028
NS	April 2028

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

Drug detail

Listed patents

Regulatory exclusivity

More from BRISTOL MYERS SQUIBB CO PHARMACEUTICAL RESEARCH INSTITUTE